Dr. Naomi Visanji is an Affiliate Scientist in the Division of Experimental & Translational Neuroscience at Krembil Research Institute, and an Assistant Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto. Her research focuses on the use of postmortem human tissues and animal models to probe the pathobiology of proteins associated with neurodegenerative disease.
She received her BSc Hons in Neuroscience from the University of Nottingham (UK) and completed her PhD in Pharmacology at King's College London (UK). She has published over 50 peer reviewed publications. She is also a Senior Scientist at Rosetta Therapeutics, a University of Toronto/MaRS Innovation UTEST startup developing new molecular matter as leads for the cure of neurodegenerative diseases.
Dr. Visanji leads the in vivo research arm of the Rossy Program for Progressive Supranuclear Palsy at the Krembil Research Institute and the Tanz Centre for Research in Neurodegenerative Diseases. Her research goals are to create a sophisticated animal model that recapitulates the full spectrum of pathology exhibited in Progressive Supranuclear Palsy to study the anatomic and cytopathologic diversity in the disease, identify the factors that contribute to disease etiology, and provide a platform for the future testing of novel therapeutics.